









Markets
/
Stocks
/
nasdaq-rprx
/

Royalty Pharma PLC

RPRX

35.627USD

-0.013-0.04%

Market hours （ET）Quotes delayed by 15 min

15.40BMarket Cap

15.09P/E TTM



Royalty Pharma PLC

35.627

-0.013-0.04%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

4 / 175

Overall Ranking

47 / 4723

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 7 analysts

Buy

Current Rating

43.445

Target Price

+22.66%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Royalty Pharma plc is a buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The Company collaborates with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. It funds innovation in the biopharmaceutical industry both directly and indirectly. Directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties. Indirectly when it acquires existing royalties from the original innovators. Its portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 14 development-stage product candidates.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 1905.47.

High Dividend

The company is a high dividend payer, with the latest dividend payout ratio of 43.83%.

Stable Dividend

The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 43.83%.

Fairly Valued

The company’s latest PE is 15.47, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 400.70M shares, increasing 0.70% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 36.17M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 9.17, which is higher than the Pharmaceuticals industry's average of 7.84. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 578.66M, representing a year-over-year increase of 7.71%, while its net profit experienced a year-over-year increase of 70.42%.

Score

Industry at a Glance

Previous score

9.17

Change



Financials

6.55

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

9.32

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 4.66, which is higher than the Pharmaceuticals industry's average of 2.06. Its current P/E ratio is 15.47, which is 193.14% below the recent high of 45.34 and 0.48% above the recent low of 15.39.

Score

Industry at a Glance

Previous score

4.67

Change

-0.01

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 4/175

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Royalty Pharma PLC is 42.50, with a high of 55.00 and a low of 34.67.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 7 analysts

Buy

Current Rating

43.445

Target Price

+22.66%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

179

Total

Median

Average

Company name

Ratings

Analysts

Royalty Pharma PLC

RPRX

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Alnylam Pharmaceuticals Inc

ALNY

Eli Lilly and Co

LLY

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 7.26, which is higher than the Pharmaceuticals industry's average of 6.64. Sideways: Currently, the stock price is trading between the resistance level at 37.25 and the support level at 34.05, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.13

Change

0.13

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(4)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.174

Sell

RSI(14)

45.515

Neutral

STOCH(KDJ)(9,3,3)

48.120

Neutral

ATR(14)

0.860

High Vlolatility

CCI(14)

-62.352

Neutral

Williams %R

51.202

Neutral

TRIX(12,20)

-0.054

Sell

StochRSI(14)

36.196

Buy

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

35.854

Sell

MA10

36.072

Sell

MA20

36.135

Sell

MA50

36.342

Sell

MA100

35.105

Buy

MA200

32.699

Buy

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Pharmaceuticals industry's average of 6.26. The latest institutional shareholding proportion is 92.75%, representing a quarter-over-quarter increase of 4.00%. The largest institutional shareholder is The Vanguard, holding a total of 36.17M shares, representing 8.37% of shares outstanding, with 0.07% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

The Vanguard Group, Inc.

Star Investors

36.48M

-1.81%

Morgan Stanley Investment Management Inc. (US)

33.11M

+2.78%

Fidelity Management & Research Company LLC

34.42M

+39.57%

Nogra Group Sicaf SIF S.A.

29.93M

-16.88%

Baillie Gifford & Co.

Star Investors

13.40M

-5.18%

BlackRock Institutional Trust Company, N.A.

16.23M

-6.47%

Swedbank Robur Fonder AB

12.16M

-0.06%

State Street Global Advisors (US)

9.52M

-2.50%

Geode Capital Management, L.L.C.

8.00M

+9.39%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 6.44, which is higher than the Pharmaceuticals industry's average of 4.07. The company's beta value is 0.59. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.